抗血管生成药治疗肝细胞癌的研究进展

Progress of antiangiogenic therapy for hepatocellular carcinoma

肝细胞癌(HCC)是一种血管丰富的癌症,抗血管生成药可通过阻断血管生成因子,抑制内皮细胞扩增及预防细胞外基质和血管基底膜降解等机制而发挥治疗肝癌的作用,加上其临床相对优良的安全性可能为肝癌治疗提供了治疗新途径。

Hepatocellular carcinoma （HCC） is a hypervascular tumor characterized by neovascularization, There are many studies demonstrate the therapeutic effect of antiangiogenic drugs on HCC, which mechanisms may include blockage of angiogenesis factor, suppressed amplification of endothelial cells and prevented degradation of extracellular matrix and vessel basement membrane. Considering its lower risk of side effects, antiangiogenic drugs may provide a novel therapeutic approach to HCC.